Updated Data for Janssen's Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study evaluating the BCMAxCD3 bispecific antibody, including progression-free survival and subgroup analyses1Data from MajesTEC-1 study published in The New England Journal of Medicine2BEERSE, Belgium--(B...

Related Keywords

United States ,American ,Jenni Mildon ,Yusri Elsayed ,Edmond Chan Mbch ,Maria Victoria Mateos ,None Of The Janssen Pharmaceutical Companies ,American Society Of Clinical Oncology ,European Commission ,Drug Administration ,Cancer Research Institute ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,European Organisation For Research ,Exchange Commission ,University Hospital Of Salamanca ,Companies Of Johnson ,European Medicines Agency ,Johnson ,American Cancer Society ,New England Journal ,Clinical Oncology ,Triple Class Exposed Multiple Myeloma ,Confidence Interval ,Consultant Physician ,University Hospital ,Prior Exposure ,Edmond Chan ,Area Lead Haematology ,Patient Reported Health Related Quality ,European Organisation ,Cancer Quality ,Life Questionnaire Core ,Vice President ,Disease Area Leader ,Hematologic Malignancies ,Janssen Research ,Orphan Drug Designation ,Breakthrough Therapy Designation ,Biologics License Application ,Pharmaceutical Companies ,Infectious Diseases ,Janssen Cilag Limited ,Private Securities Litigation Reform Act ,Janssen Pharmaceutica ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,American Society ,Participants With Relapsed ,Refractory Multiple ,Multiple Myeloma ,Clin Cancer ,Cell Therapy ,Potential Uses ,Bispecific Antibody Therapy Turns Solid Tumors ,Inflammatory Sites ,Does Not Install Protective ,Mol Cancer ,Subcutaneous Daratumumab Regimens ,Participants With Multiple ,Combination With Daratumumab Subcutaneously ,Versus Daratumumab ,Refractory Multiple Myeloma ,Serious Conditions ,Today Population Factsheets ,